ClinicalTrials.gg
Enrolling by invitationNCT07459660Updated Nov 12, 2026

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

A Phase 2 interventional study of ML-007C-MA in Psychosis Associated With Alzheimer's Disease, sponsored by MapLight Therapeutics. Enrolling by invitation at 11 sites in 3 countries. Open to participants aged 55 Years to 91 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by MapLight Therapeutics · Phase 2, Interventional, and Treatment

Updated Nov 12, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Not applicable
Ages
55 Years to 91 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
406th of 1,609
210 · median 73
Started
2026
with 90 others
Phase 2
360 of 1,940
50 open now
Primary completion
2029-03
later than 359 of 444 live
Registered
1,878th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 406th largest by planned enrollment of the 1,609 interventional ones that give a count, is one of 91 that started in 2026, is one of 360 in phase 2, reaches primary completion later than 359 of the 444 other live ones, and was the 1,878th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 91 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).

03

Conditions studied

  • Psychosis Associated With Alzheimer's Disease

Keywords

  • Alzheimer Disease
  • Brain Diseases
  • Central Nervous System Diseases
  • Delusions
  • Dementia
  • Hallucinations
  • Mental Disorders
  • Nervous System Diseases
  • Neurocognitive Disorders
  • Neurodegenerative Diseases
  • Psychotic Disorders
  • Schizophrenia Spectrum and Other Psychotic Disorders
  • Tauopathies
  • Muscarinic Antagonists
  • Muscarinic Agonists
  • Cholinergic Agents
04

Who can participate

Ages eligible
55 Years to 91 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written , or, if deemed lacking in the capacity to provide informed consent, the following requirements for consent must be met:

    1. The participant's LAR must provide written informed consent. AND
    2. The participant will provide informed assent.
  2. Has completed the Double-Blind Treatment Period of an antecedent study with ML-007C-MA (ie, ML-007C-MA-221).
  3. May benefit from long-term therapy with open-label ML-007C-MA treatment, in the judgment of the investigator.
  4. Has a designated study care partner who is in contact with the participant frequently enough to accurately report on the participant's symptoms and adherence to study drug.
  5. Resides in a stable living environment (eg, home, residential assisted living, or nursing home facility) and is expected to remain in the living situation throughout the study.

Exclusion criteria

Exclusion Criteria

  1. Under the care of hospice, bed-bound, or receiving end-of-life palliative care.
  2. Requires treatment with protocol-defined prohibited medications.
  3. Has developed a new or worsening medical comorbidity during or since the antecedent study that, in the opinion of the investigator and/or medical monitor, would compromise participant safety, interfere with the participant's ability to comply with study procedures, would preclude obtaining voluntary consent/assent, and/or would substantially impair the evaluation of study assessments.
  4. Has or had a abnormal physical examination, vital sign, or clinical laboratory safety result during or since the antecedent study that would compromise participant safety, interfere with the participant's ability to comply with study procedures, and/or would confound the interpretation of the outcome measures in the study in the opinion of the investigator.
  5. Has developed an allergy or other intolerance to ML-007C-MA, its active ingredients or their since the antecedent study.
  6. Has an elevated risk of suicidal behavior.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    ML-007C-MA

    Drug: ML-007C-MA

Interventions

  • ML-007C-MA dosed as 105/1.5 mg BID or 210/3 mg BID

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of long-term ML-007C-MA administration in participants with hallucinations and delusions associated with AD

    using the incidence of TEAEs, TE-SAEs, and TEAEs leading to study discontinuation.

    Time frame: From initial dose through end of treatment (up to 52 weeks)

07

Study locations

11 sites
  • Clinical Site
    Anaheim, California 92805, United States
  • Clinical Site
    Denver, Colorado 80218, United States
  • Clinical Site
    Doral, Florida 33122, United States
  • Clinical Site
    Miami, Florida 33155, United States
  • Clinical Site
    Miami, Florida 33173, United States
  • Clinical Site
    Miami Gardens, Florida 33014, United States
  • Clinical Site
    Orlando, Florida 32807, United States
  • Clinical Site
    Snellville, Georgia 30078, United States
  • Clinical Site
    Independence, Ohio 44131, United States
  • Clinical Site
    Pernik, Pernik 2304, Bulgaria
  • Clinical Site
    Toulouse, 31059, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2029, 36 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 36 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 10, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Clinical Site · Denver, United States
  • Clinical Site · Snellville, United States
  • Clinical Site · Independence, United States
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    3 sites added
    Show 3 added (3 United States)
    • Clinical Site · Denver, United States
    • Clinical Site · Snellville, United States
    • Clinical Site · Independence, United States
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07459660
Lead sponsor
MapLight Therapeutics
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Mar 25, 2026
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

MapLight Therapeutics
study director · MapLight Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ML-007C

Start the discussion